$RLFTF Uncle Gee Gee DD (copy) Some things I pulled out of the preprint... pretty amazing.
Important Note: Compared to the control group patients, the Aviptadil patients were coincidentally in significantly worse condition. Their “SOFA score” (which measures organ failure) was significantly worse, and the “Rothman index” (which predicts mortality) was also much worse. Aviptadil patients were already at a disadvantage over the control group, but still managed to produce the following results.
Enrolment
45 patients enrolled - All had the highest possible risk for mortality
21 were selected for Aviptadil in June & July
16 were already on ventilators
5 were already on ventilators and ECMO
24 were selected for the control group in May - Aug
11 were already on ventilators
13 were already on ventilators and ECMO
Results
19 of 21 (90%) Aviptadil patients survived to day 28
4 of 24 (19%) in the control group
4 of 5 (80%) Aviptadil patients on ECMO were removed
3 of 13 (23%) in the control group
15 of 16 (94%) Aviptadil patients on vent were removed
1 of 11 (9%) in the control group
10 Aviptadil patients returned home/care facility
2 in the control group
15 of 21 (71%) Aviptadil patients had 100+ point improvement in oxygenation
4 of 30 (13%) in the control group
Aviptadil Patient Stats
• 9-Fold advantage of survival P<.001
• 9-Fold advantage of recovery from respiratory failure P<.001
• 8 times more likely to return home or a care facility on Aviptadil
• 3-fold improvement in oxygenation
• 17 of 21 saw improvement in both lungs, 2 saw improvement in 1 lung, and 2 showed no improvement
• 2 Patients developed hypotension, which was treated
• 4 Patients developed diarrhea, which was treated
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
Important Note: Compared to the control group patients, the Aviptadil patients were coincidentally in significantly worse condition. Their “SOFA score” (which measures organ failure) was significantly worse, and the “Rothman index” (which predicts mortality) was also much worse. Aviptadil patients were already at a disadvantage over the control group, but still managed to produce the following results.
Enrolment
45 patients enrolled - All had the highest possible risk for mortality
21 were selected for Aviptadil in June & July
16 were already on ventilators
5 were already on ventilators and ECMO
24 were selected for the control group in May - Aug
11 were already on ventilators
13 were already on ventilators and ECMO
Results
19 of 21 (90%) Aviptadil patients survived to day 28
4 of 24 (19%) in the control group
4 of 5 (80%) Aviptadil patients on ECMO were removed
3 of 13 (23%) in the control group
15 of 16 (94%) Aviptadil patients on vent were removed
1 of 11 (9%) in the control group
10 Aviptadil patients returned home/care facility
2 in the control group
15 of 21 (71%) Aviptadil patients had 100+ point improvement in oxygenation
4 of 30 (13%) in the control group
Aviptadil Patient Stats
• 9-Fold advantage of survival P<.001
• 9-Fold advantage of recovery from respiratory failure P<.001
• 8 times more likely to return home or a care facility on Aviptadil
• 3-fold improvement in oxygenation
• 17 of 21 saw improvement in both lungs, 2 saw improvement in 1 lung, and 2 showed no improvement
• 2 Patients developed hypotension, which was treated
• 4 Patients developed diarrhea, which was treated
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
1
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
